







an Open Access Journal by MDPI

Study of Inherited Retinal Diseases—Volume II

Guest Editor:

Prof. Dr. Se Joon Woo

Professor of Department of Ophthalmology, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Republic of Korea

Deadline for manuscript submissions:

15 October 2024

Message from the Guest Editor

Inherited retinal disease (IRD) is a major cause of bilateral visual decline and blindness worldwide. To date, there is no definitive treatment option for this condition. Recently, there have been advances in the field of genetic diagnosis, and new treatment methods have been introduced, including gene therapy and genome editing. Since the approval of gene therapy for RPE65-related IRD, the future of IRD treatment appears bright, and more patients with IRD may be saved from blindness as technology develops. To reach a better visual outcome for IRD patients, a greater understanding of IRD, including the genetics, mechanism, clinical features, and preclinical and clinical trial results related to the conditions, is needed by physicians, researchers, and patients alike, as well as pharmaceutical companies and governments.

In this Special Issue, we welcome reviews and original articles about the study of IRD. These include, but are not limited to, the genetic and molecular mechanisms of IRD, diagnosis, clinical features and imaging of IRD cases, epidemiology, ethnic variability, preclinical research, and clinical trials of new treatments. We look forward to your contributions.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank: JCR - Q2 (*Genetics & Heredity*) / CiteScore - Q2 (*Genetics*)

Contact Us